Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PKMYT1 siRNA
- Development stage
- Preclinical
- Lead developer
- National Cancer Institute
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Localized
01
Overview
PKMYT1 siRNA is a small interfering RNA (siRNA) therapeutic candidate designed to silence the expression of the PKMYT1 (Protein Kinase, Membrane Associated Tyrosine/Threonine 1) gene. PKMYT1 is a critical regulator of the cell cycle, specifically the G2/M transition, where it phosphorylates and inhibits CDK1. In research led by the National Cancer Institute (NCI), PKMYT1 siRNA is being evaluated as part of a synthetic lethal strategy for the treatment of Diffuse Pleural Mesothelioma (DPM). When used in combination with WEE1 siRNA, it induces robust knockdown of its target, leading to significant G2/M arrest, depletion of S-phase cells, and synergistic induction of apoptosis. The therapeutic is delivered via a specialized nanoparticle-hydrogel system designed for localized RNA delivery to anatomically restricted, treatment-refractory cancers.
- Other names
- siPKMYT1siPKMYT-1siPKMYT 1PKMYT1 small interfering RNAPKMYT-1 small interfering RNAPKMYT 1 small interfering RNA
02
Targets
PKMYT1 (Protein kinase membrane associated tyrosine/threonine 1)
Beyond the preview
Go deeper on PKMYT1 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PKMYT1 siRNA.